NASDAQ
Immix Biopharma, Inc. (IMMX)
♥ 691 Thanks from members
Immix Biopharma, Inc. (IMMX) exhibits a strong clinical-stage biotechnology profile characterized by advanced trial enrollment in NEXICART-2, high complete response rates, and major regulatory designations, tempered by widening net losses, non-existent product revenue, and divergent near-term valuation metrics from analysts.